Kite Pharma to Present Four Abstracts, including Safety and Efficacy Data from the KTE-C19 Phase 1 Study in Patients with Refractory, Aggressive NHL (ZUMA-1), at the 57th American Society of Hematology Annual Meeting (ASH)
05 nov. 2015 09h00 HE
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today announced upcoming presentations related to KTE-C19, Kite's lead product candidate, that will take...
Kite Pharma to Present at Upcoming Investor Conferences in November 2015
04 nov. 2015 08h00 HE
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Nov. 4, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) today announced that management will present at several upcoming investor conferences this month:
Credit...
Kite Pharma Initiates ZUMA-1 Phase 2 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma (NHL) to Support Registration of KTE-C19
02 nov. 2015 08h00 HE
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma and Alpine Immune Sciences Announce Research Collaboration and License Agreement to Enhance Immune Response in the Tumor Microenvironment
27 oct. 2015 08h00 HE
|
Kite Pharma, Inc.
SANTA MONICA, Calif. and SEATTLE, Oct. 27, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today announced that it has entered into a worldwide research and license agreement with...
Kite Pharma Announces Exclusive License with the National Institutes of Health for T Cell Receptor (TCR)-Based Products to Treat Tumors Expressing MAGE
20 oct. 2015 08h00 HE
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Oct. 20, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma Receives Positive Opinions for Orphan Drug Designation in the European Union (EU) for KTE-C19 in Three Additional Hematological Indications
15 oct. 2015 08h00 HE
|
Kite Pharma, Inc.
COMP Opinions Recommend EU Orphan Designation for the Treatment of Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), and Follicular Lymphoma...
Kite Pharma Commends Steven A. Rosenberg, M.D., Ph.D., on the Prestigious Medal of Honor Award From the American Cancer Society
07 oct. 2015 08h00 HE
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Oct. 7, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today announced that Steven A. Rosenberg, M.D., Ph.D., Chief of Surgery at the National Cancer Institute...
Kite Pharma Announces Peer-Reviewed Publication of T Cell Receptor Based Product Candidate to Treat HPV-Associated Cancers
01 oct. 2015 05h01 HE
|
Kite Pharma, Inc.
- TCR product candidate targeting human papillomavirus (HPV)-16 E6 selectively kills cervical and head and neck cancer cells
- Phase 1/2 clinical trial of the HPV-16 E6 TCR is enrolling patients...
Kite Pharma to Present at IBC Life Sciences' IMMUNO-ONCOLOGY: Advancing the Next Generation of Cancer Immunotherapies Conference
24 sept. 2015 08h00 HE
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Sept. 24, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today announced that Marc Better Ph.D., Vice President, Product Sciences, will present during the...
Franz B. Humer, Former Chairman and CEO of Roche Group, Appointed to Kite Pharma's Board of Directors
15 sept. 2015 03h00 HE
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Sept. 15, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today announced that Dr. Franz B. Humer, the former Chairman and Chief Executive of Roche Holding Ltd.,...